

dexcomG6[®]

Continuous Glucose Monitoring (CGM) System Has Broad Coverage in

The Future of CGM Is Here

- **New** Urgent Low Soon alert
- **No fingersticks** needed for calibration, treatment decisions and insulin dosing^{1*}
- **Accurate glucose readings** even when taking acetaminophen^{2†}
- **10-day wear** sensor



Dexcom receiver is included in the Dexcom G6 CGM System. Smart devices sold separately.[†]

COVERAGE SUMMARY³

PLAN NAME	COVERAGE STATUS	BENEFIT TYPE
-----------	-----------------	--------------

Eligible patients can save up to \$140 on the Dexcom G6®

Offer Details

Commercially insured patients using Dexcom G6 may be eligible for copay savings. §

How the co-pay savings are applied:

UP TO
\$60

Applied to your co-pay for one receiver

UP TO
\$60

Applied to your co-pay for the transmitter

UP TO
\$20

Off one sensor 3-pack (in excess of \$60 co-pay)

\$140 Total Potential Savings

SAVE UP TO \$140*
OFF YOUR DEXCOM G6 CGM SYSTEM

Must activate or use by 12/31/2019

dexcom G6®

BIN# 000000
PCN# XX
GRP# 0000000000
ID# 0000000000

*Maximum savings limit applies; patient out-of-pocket expense may vary. Please see back of card for Program Terms, Conditions, and Eligibility Criteria.

www.dexcom.com/pharmacyoffer

BRIEF SAFETY STATEMENT Indications for Use: The Dexcom G6 Continuous Glucose Monitoring System (G6) is an autonomous, real-time, continuous glucose monitoring device indicated for the management of diabetes in persons age 2 years and older. The glucose measurements are intended to replace fingerstick blood glucose testing for diabetes treatment decisions and behavioral modifications. The G6 can communicate wirelessly to and from other interoperable devices. Contraindication: Do not wear your G6 (sensor, transmitter, receiver, or smart device) for magnetic resonance imaging (MRI), computed tomography (CT) scan, or high-frequency electrical heat (diathermy) treatment. It is MR Unsafe. Warning: Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at <https://www.dexcom.com/safetyinformation> and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms or expectations or you're taking over the recommended maximum dosage amount of 1000 mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

*If your glucose alerts and readings from the G6 do not match symptoms or expectations, or you're taking over the recommended maximum dosage amount of 1000 mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions.

†G6 readings can be used to make diabetes treatment decisions when taking up to a maximum acetaminophen dose of 1000 mg every 6 hours. Taking a higher dose may affect the G6 readings.

‡For a list of compatible devices, please visit dexcom.com/compatibility.

§Eligibility Requirements: The savings programs are offered to commercially insured patients aged 2 years and older ONLY. This program is not open to patients receiving prescription reimbursement under any federal-, state-, or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), the Department of Defense (DoD) or TRICARE® or where prohibited by law.

References: 1. Aleppo G, Ruedy KL, Kruger AL, et al. REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes. *Diabetes Care*. 2017;40(4):538–545. 2. Calhoun P, Johnson TK, Hughes J, Price D, Baló AK. Resistance to acetaminophen interference in a novel continuous glucose monitoring system. *J Diabetes Sci Technol*. 2018;12(2):393–396. 3. Data on file, Dexcom, Inc.

Please see back of card for Program Terms, Conditions, and Eligibility Criteria.